Actimed Therapeutics Closes £5M Second Tranche of £10M Seed Financing

Actimed Therapeutics, a London, UK-based scientific stage pharmaceutical firm, closed its second and ultimate £5M tranche of Seed financing.

The closing of this spherical, led by Mankind Pharma, brings the entire seed funding raised by Actimed to roughly £10M. Following this financing, Atish Majumdar, President (Sales & Marketing) of Mankind Pharma joined Actimed Therapeutics as a member of its Board of Directors.

The firm intends to make use of the funds to assist the event of its portfolio, together with preparation for the Phase 2b/3 programme for its lead asset, S-pindolol benzoate, being developed for the therapy of most cancers cachexia.

Founded in 2017 by Stefan Anker, Andrew Coats, and Yann Colardelle, and led by CEO Robin Bhattacherjee, Actimed Therapeutics is a scientific stage specialty pharmaceutical firm centered on bringing innovation to the therapy of muscle losing problems to rework the care of an underserved and weak affected person inhabitants. The lead space of focus for Actimed is particularly in cachexia. Cachexia is a losing illness that’s related to most cancers and different critical continual diseases and with important morbidity and mortality. Its lead product, S-pindolol benzoate (ACM-001.1) targets a number of pathways that drive cachexia and has generated promising proof of idea Phase 2a scientific knowledge in cachexia sufferers. Actimed is at the moment getting ready for additional part 2b/3 scientific research in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC). 



Leave a Comment